You may also like
Hemoadsorption Eliminates Remdesivir from the Circulation: Implications for the Treatment Of COVID-19
Remdesivir and its main active metabolite GS‐441524 are rapidly eliminated from the perfusate by the CytoSorb® adsorber device in vitro. This should be considered in patients for whom both therapies are indicated, and simultaneous application should be avoided. In general, plasma levels of therapeutic drugs should be closely monitored under concurrent CytoSorb® therapy.
1 min read
ECMO in COVID19: The Power of Connection
The power of connection: at a time when social distancing is a universal necessity, connecting as a healthcare community has never been so vitally important to keeping our patients & colleagues safe.
1 min read
The Cost Impact of Short-Term Ventricular Assist Devices and Extracorporeal Life Support Systems Therapies on the National Health Service in the UK
The objective of the study was to assess the cost of using different blood pumps for short-term ventricular assist device (VAD) andextracorporeal life support (ECLS) systems for cardiac and cardiorespiratory failure in the UK.
1 min read